Aurelia Santoro, Paola Siviero, Nadia Minicuci, Elena Bellavista, Michele Mishto, Fabiola Olivieri, Francesca Marchegiani, Andrea Maria Chiamenti, Luisa Benussi, Roberta Ghidoni, Benedetta Nacmias, Silvia Bagnoli, Andrea Ginestroni, Osvaldo Scarpino, Emidio Feraco, Walter Gianni, Guido Cruciani, Roberto Paganelli, Angelo Di Iorio, Mario Scognamiglio, Luigi Maria Edoardo Grimaldi, Carlo Gabelli, Sandro Sorbi, Giuliano Binetti, Gaetano Crepaldi, Claudio Franceschi
Acetylcholinesterase inhibitors (AChEIs) have been used to improve cognitive status and disability in patients with mild to moderate Alzheimer's disease (AD). However, while the efficacy of AChEIs (i.e. how they act in randomized controlled trials) in this setting is widely accepted, their effectiveness (i.e. how they behave in the real world) remains controversial. To compare the effects of three AChEIs, donepezil (Aricept), galantamine (Reminyl) and rivastigmine (Exelon), in an Italian national, prospective, observational study representative of the 'real world' clinical practice of AChEI treatment for AD...
February 2010: CNS Drugs